Filing summary
Entity mismatch: The request identifies Bio Green Med Solution, Inc., but the supplied Form 10-K is for Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC; preferred stock: CYCCP). This summary describes the filing provided, not the named company.
Business context and reporting period
This is Cyclacel’s annual report for the fiscal year ended December 31, 2022, filed March 8, 2023. Cyclacel is a clinical-stage biopharmaceutical company developing cancer drugs. Its principal programs are fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor. Neither candidate is approved for sale, and the company reported no revenue in 2022 or 2021.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $20.3 million | $15.5 million |
| General and administrative expense | $7.4 million | $7.5 million |
| Operating loss | $27.7 million | $22.9 million |
| Net loss | $21.2 million | $18.9 million |
| Net loss per common share, basic and diluted | $1.90 | $2.14 |
| Net cash used in operating activities | $20.8 million | $18.5 million |
| Cash and cash equivalents at year-end | $18.3 million | $36.6 million |
| Working capital at year-end | $17.0 million | $35.6 million |
R&D expense rose 31%, reflecting higher clinical-development costs for both lead programs. Other income was $1.7 million, including $1.3 million of royalties under a historical asset purchase agreement; the company says timing and amount of future receipts are unpredictable. A $4.7 million UK R&D tax benefit partially offset the 2022 loss. With no revenue, conventional operating margins are not meaningful.
Total liabilities were $7.5 million at year-end, including $2.6 million of accounts payable and $4.8 million of accrued and other current liabilities; the filing does not identify material borrowings. The company reported $4.0 million of liquidation preference on its 6% convertible exchangeable preferred stock and $0.7 million of accumulated unpaid preferred dividends. It paid or accrued approximately $0.2 million of preferred dividends in 2022.
Changes, outlook and material matters
- Cash declined by $18.2 million during 2022. Operating cash use of $20.8 million was partly offset by $3.0 million of net financing cash, principally ATM share-sale proceeds net of preferred dividends.
- Management estimated that year-end cash would fund operations only through the fourth quarter of 2023 and disclosed substantial doubt about the company’s ability to continue as a going concern for at least twelve months after issuance of the financial statements. Planned equity or debt financing and partnerships are not assured.
- Management expected 2023 R&D and general and administrative expenses to be broadly similar to 2022 levels, while continuing Phase 1/2 trials. No revenue guidance was provided; the company does not expect revenue in the foreseeable future.
- At year-end, fadraciclib’s oral solid-tumor study had dosed 24 patients across seven escalation levels; its oral hematologic-malignancy study had enrolled eight patients. Plogosertib’s oral solid-tumor study had treated nine patients at three dose levels, with no dose-limiting toxicities reported to that point. These are early clinical observations, not proof of efficacy.
- In 2022, Cyclacel sold 3,117,100 shares for approximately $4.5 million after its associated shelf registration statement had expired. Potential purchaser rescission rights led the company to classify the proceeds as temporary equity. No claims or demands had been reported by year-end; the potential exposure could be material.
- On January 4, 2023, Nasdaq notified the company that its share price failed the $1.00 minimum bid requirement and provided a 180-day compliance period ending July 3, 2023. The filing states there was no assurance of regaining compliance.
- Unrealized foreign-exchange losses on long-term intercompany loans were $21.2 million in 2022 and were recorded in other comprehensive loss, not net loss. The auditor issued an unqualified opinion on the financial statements while highlighting the going-concern uncertainty; the audit identified clinical-trial accruals as a critical audit matter.
- The company reported no material legal proceedings as of December 31, 2022 and stated management assessed internal control over financial reporting as effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Review subsequent financing, cash burn and operating runway, given the going-concern disclosure and estimated runway through Q4 2023.
- Check the status and potential resolution of rescission rights and regulatory exposure related to the approximately $4.5 million of post-expiration ATM sales.
- Verify Nasdaq bid-price compliance and any effect on listing or access to capital markets.
- Track updated clinical-trial enrollment, safety, dose selection and efficacy data for fadraciclib and plogosertib; distinguish preliminary or biomarker findings from validated clinical benefit.
- Assess potential dilution from future fundraising, outstanding warrants and convertible preferred securities, and consider preferred dividends and liquidation preferences.